Fluvoxamine for the treatment of COVID-19

Marzolini, C.; Marra, F.; Boyle, A.; Khoo, S.; Back, D. J.

doi:10.1016/S2214-109X(21)00592-1

Fluvoxamine for the treatment of COVID-19

Détails

Télécharger: 35180411_BIB_A6D6B687283D.pdf (98.79 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée

ID Serval

serval:BIB_A6D6B687283D

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Editorial

Collection

Publications

Institution

UNIL/CHUV

Titre

Fluvoxamine for the treatment of COVID-19

Périodique

Lancet Glob Health

Auteur⸱e⸱s

Marzolini C., Marra F., Boyle A., Khoo S., Back D. J.

ISSN

2214-109X (Electronic)

ISSN-L

2214-109X

Statut éditorial

Publié

Date de publication

03/2022

Peer-reviewed

Oui

Volume

10

Numéro

3

Pages

e331

Langue

anglais

Notes

Marzolini, Catia
Marra, Fiona
Boyle, Alison
Khoo, Saye
Back, David J
eng
MR/V020498/1/MRC_/Medical Research Council/United Kingdom
MR/V028391/1/MRC_/Medical Research Council/United Kingdom
Comment
Letter
England
Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1.

Mots-clé

*Fluvoxamine/therapeutic use, Humans, SARS-CoV-2, *COVID-19 Drug Treatment

URN

urn:nbn:ch:serval-BIB_A6D6B687283D1

OAI-PMH

oai:serval.unil.ch:BIB_A6D6B687283D

DOI

10.1016/S2214-109X(21)00592-1

Pubmed

35180411

Création de la notice

25/08/2023 6:17